Spyre Therapeutics announced positive 12-week induction topline data from Part A of the Phase 2 SKYLINE trial for SPY003, an anti-IL-23 antibody being investigated for moderately-to-severely active ulcerative colitis. The drug met its primary endpoint with a statistically significant 10.0-point reduction in Robarts Histopathology Index (RHI) score (p<0.0001), alongside clinical remission and endoscopic improvement rates of 20% and 30%, respectively. This result establishes proof-of-concept for all three monotherapy components (SPY001, SPY002, and SPY003) in the company's inflammatory bowel disease portfolio. The filing confirms that Part B of the SKYLINE trial is actively enrolling combination arms, with topline induction data expected in 2027. Spyre Therapeutics operates as a clinical-stage biotechnology company developing next-generation immunology and inflammation therapies.

Spyre Therapeutics announced topline results from the rheumatoid arthritis (RA) sub-study of its Phase 2 SKYWAY basket trial evaluating SPY072. Both low and high doses demonstrated statistically significant benefits compared to placebo on primary or secondary endpoints, including DAS28-CRP and ACR20/ACR50 responses at Week 12. The drug was well-tolerated with a safety profile consistent with the TL1A class. However, the magnitude of efficacy did not meet the company's internal bar to prioritize SPY072 as a monotherapy in RA. The results provide proof-of-mechanism for TL1A inhibition and support its potential in other autoimmune diseases and as a combination component. Spyre Therapeutics is a clinical-stage biotechnology company developing next-generation immunology therapies.

Spyre Therapeutics reported second quarter 2026 financial results on August 4, 2026, announcing a net loss of $36.2 million compared to $36.7 million in the prior year period. The company raised $435.2 million in net proceeds from a public offering of common stock in April 2026, resulting in a cash position of $1.1 billion as of June 30, 2026. Research and development expenses increased to $65.5 million from $40.1 million year-over-year due to higher manufacturing and clinical trial costs. The company also recognized a $40.0 million gain on the sale of in-process research and development assets related to pegzilarginase rights sold to Immedica Pharma AB. Spyre Therapeutics is a clinical-stage biotechnology company developing next-generation immunology therapies for inflammatory bowel disease and rheumatic diseases.

Spyre Therapeutics announced positive 12-week induction topline data from Part A of its Phase 2 SKYLINE trial for SPY002, targeting moderately-to-severely active ulcerative colitis. The drug met its primary endpoint with a statistically significant 10.7-point reduction in the Robarts Histopathology Index (p<0.0001). Clinical remission was achieved in 33% of participants, and 42% showed endoscopic improvement. The safety profile was consistent with the TL1A class, with 41.7% of subjects experiencing any adverse event and two serious adverse events reported, both deemed not drug-related. Spyre Therapeutics is a biotechnology company developing therapies for inflammatory diseases.